Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

“…2 Based on this difference in length of exacerbation, we chose to assume a 63% reduction in resource use intensity, which corresponds to a decrease from 12.7 days to 7.8 days. 26 Change in lung function-The systematic review conducted by the Cochrane Airways Group suggests a small improvement in FEV 1 percent predicted 25 associated with omalizumab therapy. The systematic review finds an improvement in FEV 1 percent predicted of 2.9% in subjects treated with omalizumab.…”

“…In our sensitivity analyses we explored a range of 33% to 92%, based on previously published studies. 26 Reduced duration/intensity of hospitalizations-Modeled as a percentage reduction in the severity of acute events, omalizumab would affect the resource use of urgent care visits, ED visits, and hospitalizations. Omalizumab treatment resulted in shorter duration of asthma exacerbations in one clinical trial, with a mean length of exacerbation of 7.8 days compared with 12.7 days in the control group (P < .001).…”

“…Baseline input values and parameters for sensitivity analyses are listed in Table I. 2,[25][26][27][28] Reduction in exacerbation rate-The Cochrane Airways Group's review of omalizumab found a 46% reduction in the rate of exacerbation in subjects receiving omalizumab plus an ICS compared with that seen in the subjects receiving an ICS alone. 24 Thus in our base-case analysis we assumed a 46% reduction in the exacerbation rate.…”

Anticorpo monoclonal anti-IgE no tratamento da asma e de outras manifestações relacionadas a doença alérgica

“…17 A clinical trial involving 1,405 patients with moderate and severe asthma demonstrated that anti-IgE reduced the rate of severe exacerbations and reduced emergency service usage and hospitalizations. 35 According to a systematic Cochrane review, omalizumab was capable of exhibiting a reductive effect on steroid use, but that the advantage of that effect should be evaluated in terms of its cost/benefit ratio. Further studies into this aspect are needed, especially ones including pediatric patients.…”

Intubation secondary to asthma exacerbation in a patient with asthma receiving xolair (omalizumab)

“…There have been multiple studies to date published on the clinical efficacy of omalizumab. [3][4][5][6][7][8][9][10] Those studies demonstrated a substantial clinical benefit with the use of omalizumab, with significantly fewer asthma exacerbations per patient; although some limitations were seen in patients with FEV1 > 80% predicted or in chronic systemic steroids. Direct telephonic conversations with Genentech revealed that a 55-yearold male with mitral valve prolapse, hypertension, and previous history of intubations due to asthma had another exacerbation that required intubation during the omalizumab trials.…”